{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:09:38Z","timestamp":1755220178574,"version":"3.43.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>Patient*innen mit malignen Erkrankungen werden Impfungen gegen COVID-19, Influenza; Pneumokokken und RSV empfohlen. Bei &gt;50-J\u00e4hrigen wird zum Schutz vor Zoster-Reaktivierungen au\u00dferdem eine VZV-Impfung mittels Totimpfstoff empfohlen. PCV20 ist nun der pr\u00e4ferierte Impfstoff, um einen optimalen Schutz gegen Pneumokokken zu erreichen. Zur Influenzaprophylaxe sollen in Zukunft tri- statt tetravalente Impfstoffe verwendet werden. Die durch CAR-T-Zell-Therapie ausgel\u00f6ste profunde B-Zell-Depletion wird zunehmend in Impfempfehlungen ber\u00fccksichtigt.<\/jats:p><jats:p>F\u00fcr bestimmte Hochrisikosituationen ist eine antibiotische Prophylaxe mittels Fluorchinolon weiterhin empfohlen. Angesichts zunehmender Resistenzentwicklung und relevanter Nebenwirkungen werden diese zunehmend kritisch diskutiert. Die Empfehlungen zur PJP-Prophylaxe f\u00fcr Hochrisikopatienten bleiben im Wesentlichen bestehen.<\/jats:p><jats:p>Posaconazol wird als Standardprophylaxe bei Patient*innen mit \u00fcber 7 Tage andauernder Neutropenie von &lt;0,5 G\/l und h\u00e4matologischer Neoplasie empfohlen. Isavuconazol bietet eine wirksame Alternative bei Unvertr\u00e4glichkeit von Posaconazol. Interaktionen zwischen Antimykotika (z.B. Azole durch CYP450-Hemmung) und onkologischen Therapien, aber auch Standardmedikation, z.B. DOAK sind klinisch relevant. Nicht-pharmakologische Ma\u00dfnahmen zur Vermeidung von Pilzinfektionen sind nun Teil der Leitlinienempfehlungen. Insbesondere ein Rauchstopp ist zu empfehlen.<\/jats:p><jats:p>Letermovir ist aktuelles Standardmedikament zur CMV-Prophylaxe. Eine medikament\u00f6se Prophylaxe von COVID-19 wird in der Regel nicht empfohlen.<\/jats:p><jats:p>Die Schwellenwerte zur Indikation einer Prim\u00e4rprophylaxe wurden reduziert: Bei &gt;20% FN-Risiko ist G-CSF empfohlen. Auch bei einem FN-Risiko von &gt;10% und patienteninh\u00e4renten Risikofaktoren wird G-CSF empfohlen. Ein nicht PEG-haltiges langwirksames G-CSF-Pr\u00e4parat wurde 2024 zugelassen.<\/jats:p>","DOI":"10.1055\/a-2414-8494","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T22:52:30Z","timestamp":1754607150000},"page":"1013-1018","source":"Crossref","is-referenced-by-count":0,"title":["Immunsuppression bei Krebs: Schutz vor Infektionen"],"prefix":"10.1055","volume":"150","author":[{"given":"Charlotte","family":"Schwicht","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik III, LMU M\u00fcnchen, M\u00fcnchen, GERMANY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik III, LMU M\u00fcnchen, M\u00fcnchen, GERMANY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik III, LMU M\u00fcnchen, M\u00fcnchen, GERMANY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00103-020-03123-w","article-title":"Impfen bei Immundefizienz","volume":"63","author":"H-J Laws","year":"2020","journal-title":"Bundesgesundheitsblatt \u2013 Gesundheitsforschung \u2013 Gesundheitsschutz"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","article-title":"Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"100","author":"M Christopeit","year":"2021","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors \u2013 Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"CT Rieger","year":"2018","journal-title":"Ann Oncol"},{"key":"ref5","first-page":"9","article-title":"Beschluss f\u00fcr die Empfehlung der STIKO zum Wechsel von quadrivalenten zu trivalenten Influenza-Impfstoffen","author":"Robert-Koch-Institut","year":"2024","journal-title":"Epidemiologisches Bulletin"},{"key":"ref6","first-page":"3","article-title":"Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen \u2265 60 Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung","author":"Robert-Koch-Institut","year":"2023","journal-title":"Epidemiologisches Bulletin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults With Cancer: ASCO Guideline","volume":"42","author":"M Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100445","article-title":"Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium","volume":"19","author":"TK Choueiri","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/djad015","article-title":"COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)","volume":"115","author":"AF Best","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study","volume":"72","author":"MA Andersen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.vaccine.2024.01.004","article-title":"A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults \u2265 60 years of age in Japan, South Korea, and Taiwan","volume":"42","author":"M Haranaka","year":"2024","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"AL Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"09","key":"ref15","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"DM Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/jco.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"RA Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"J Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","article-title":"Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus","volume":"101","author":"L Henze","year":"2022","journal-title":"Ann Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy","volume":"136","author":"W Cao","year":"2020","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/annonc\/mdu035","article-title":"Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)","volume":"25","author":"JJ Vehreschild","year":"2014","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1186\/s12885-024-12892-5","article-title":"A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer","volume":"24","author":"Q Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"ref24","first-page":"525","article-title":"St\u00e4ndige Impfkommission (STIKO): Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes-zoster-subunit-Totimpfstoff","volume":"50","year":"2018","journal-title":"Epid Bull"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2414-8494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T22:52:34Z","timestamp":1754607154000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2414-8494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":19,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2414-8494","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}